<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01424371</url>
  </required_header>
  <id_info>
    <org_study_id>2011-071</org_study_id>
    <nct_id>NCT01424371</nct_id>
  </id_info>
  <brief_title>Adjuvanted Influenza Vaccine Effectiveness in the Elderly (65+Yrs)</brief_title>
  <official_title>A Case-Control Study to Evaluate the Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine in the Elderly Aged ≥65 Years.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fraser Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fraser Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study explores the hypothesis that the use of an adjuvanted influenza vaccine in the
      elderly will produce greater vaccine effectiveness in their group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the effectiveness of adjuvanted trivalent inactivated influenza vaccine in the
      elderly (aged ≥ 65 years) through the reduction in relative risk of microbiologically
      confirmed influenza illness
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">April 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Vaccine effectiveness against laboratory confirmed influenza illness</measure>
    <time_frame>Influenza season 2011/12 and 2012/13</time_frame>
    <description>Evaluation of the effectiveness of an adjuvanted TIV in the elderly aged ≥65 years, through the reduction in relative risk of microbiologically confirmed influenza illness</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Adjuvanted Vaccine Group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Unadjuvanted Vaccine Group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Unvaccinated Elderly</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All elderly over 65 years in the lower mainland of British Columbia presenting with an
        influenza-like-illness
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.Elderly tested for influenza as part of routine clinical care in the Lower Mainland and
        on Vancouver Island during the influenza season.

        Cases: Proven influenza diagnosed on naso-pharyngeal swab via PCR Controls: Elderly with
        influenza-like-illness testing negative for influenza during the influenza season.

        Exclusion Criteria:

          1. Known immunodeficiency disorders (including HIV)

          2. Current or recent (within 90 days prior to first dose of influenza vaccine)
             immunosuppressive treatment including chronic oral steroids (1mg/kg for &gt; 4 weeks),
             cytotoxic chemotherapy, radiation therapy, other immunosuppressive drug and biologic
             agents Note: Use of topical or inhalant corticosteroids is acceptable.

          3. Administration of immunoglobulins during the study period;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>PAUL G VAN BUYNDER, MBBS MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fraser Health Authority</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>PAUL G VAN BUYNDER, MBBS MPH</last_name>
    <phone>6044187497</phone>
    <email>paul.vanbuynder@fraserhealth.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fraser Health Authority</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3T 5H5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>PAUL G VAN BUYNDER, MBBS MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2011</study_first_submitted>
  <study_first_submitted_qc>August 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2011</study_first_posted>
  <last_update_submitted>September 28, 2012</last_update_submitted>
  <last_update_submitted_qc>September 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fraser Health</investigator_affiliation>
    <investigator_full_name>Paul VanBuynder</investigator_full_name>
    <investigator_title>Chief Medical Health Officer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

